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Cerebrospinal fluid chitotriosidase concentration reflects microglial activation in the spinal 
cord of in amyotrophic lateral sclerosis patients. 
 
Chitin is a long chain insoluble carbohydrate polymer that is one of the most abundant organic 
materials in the biosphere, second only to cellulose.1 It occurs as a key structural molecule in 
the exoskeleton of invertebrates and cell walls of fungi. It builds up the shells of oysters and 
clams. Its durable properties are the subject of intense study in biotechnology and materials 
science. There has been a long-standing assumption that chitin plays no role in vertebrate 
biology, but this is starting to change; expression of chitin in vertebrate tissues has been 
verified and potential biological functions of the polymer in higher organisms are just being 
unravelled.1  
 
Chitinases constitute a widely expressed family of hydrolases that cleave chitins. Insects 
produce chitinases to facilitate moulting. Microorganisms produce them to digest nutrients. 
The function of chitinases in vertebrates remains unclear, but potentially they play a role in 
the innate immune system defense against, e.g., fungi and bacteria. The first human chitinase 
to be cloned and characterised was chitotriosidase, also known as chitinase 1, CHIT1 or ChT. 
The gene (CHIT1) is found on chromosome 1 and encodes a neutral-acting glycosyl hydrolase 
that is expressed in monocytes and macrophages and, hence, also in miroglia (the resident 
macrophages of the central nervous system [CNS]). Activation of macrophages and microglia 
results in increased expression and secretion of chitotriosidase. There are also chitinase-like 
proteins that bind chitin but lack enzymatic activity. A well-studied member of the chitinase-
like protein family is YKL-40.   
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Although the biological function of chitotriosidase in humans remains elusive, the enzyme has 
been explored as a potential biomarker for macrophage and/or microglial activation. Patients 
with Gaucher’s disease, an inherited lysosomal storage disease, have macrophages engorged 
with lysosomal glucocerebroside. In response to this, the macrophages secrete enormous 
amounts of chitotriosidase; a patient with Gaucher’s disease may have a 1000-fold increase in 
the blood level of the protein compared with normal controls. This can be used both as a 
diagnostic biomarker and as a marker to follow the effect of treatment.  
 
In neurodegenerative diseases, most studies on microglial biomarkers have been performed in 
Alzheimer’s disease (AD). Recent reports suggest that the cerebrospinal fluid (CSF) 
concentration of the secreted ectodomain of triggering receptor expressed on myeloid cells 2 
(Trem2), a molecule that is selectively expressed on microglia in the CNS and genetically 
linked to AD, is increased in AD and correlates with CSF tau protein concentration (a marker 
of axonal degeneration in AD) (http://www.alzforum.org/alzbiomarker/meta-
analysis/alzheimers-disease-vs-control-strem2-csf). These results are backed by an extensive 
literature showing increased CSF concentrations of other microglia- and/or macrophage-
derived proteins, including chitotriosidase and YKL-40.2 When measured in blood, the 
concentrations of most of the microglia-related proteins are higher than in CSF and probably 
reflect release from monocytes and macrophages in peripheral blood rather than CNS-related 
changes.  
 
In the current issue of JNNP, Steinacker et al. report on chitotriosidase concentrations in CSF 
and serum from patients with amyotrophic lateral sclerosis (ALS) compared with results 
obtained from patients with a broad range of other neurodegenerative diseases, including 
frontotemporal dementia, AD, Parkinson’s disease and Creutzfeldt-Jakob’s disease (CJD), as 
 4
well as both neurologically healthy controls and ALS mimics.3 There was a striking increase 
in CSF chitotriosidase concentration (measured by enzyme-linked immunosorbent assay; 
there are also assays for chitotriosidase activity but for those one needs to take a common 
CHIT1 polymorphism that renders the enzyme inactive into account4) in ALS compared with 
all other diagnostic groups, except CJD. The highest concentrations were seen in patients with 
rapidly progressive ALS and there were positive correlations with both neurofilament light 
and heavy concentrations (classical markers of axonal degeneration in ALS), suggesting that 
CSF chitotriosidase concentration could be a disease activity marker in ALS. Additionally, 
the authors verified that chitotriosidase expression in the spinal cord was confined to cells that 
stained positively with microglia and macrophage markers (the staining was particularly 
strong in the spinal cord from ALS patients). No robust changes in chitotriosidase 
concentration were detected in blood, suggesting that a large proportion of blood-based 
chitotriosidase is derived from non-CNS sources, similar to what has been seen in studies of 
AD. 
 
Taken together, Steinacker et al. demonstrate prominent microglial activation in the spinal 
cord of ALS patients. This activation correlates with clinical and biochemical markers of 
disease activity and can be quantified using an assay for CSF chitotriosidase. The results point 
towards microglial activation as an important feature of ALS pathophysiology and a potential 
therapeutic target. However, before such a conclusion can be drawn, longitudinal studies with 
repeated samplings are needed to elucidate when, during the disease course, the microglial 
activation signal becomes apparent and how CSF chitotriosidase concentration changes with 
disease progression. Are patients with the highest increase in CSF chitotriosidase 
concentration over time better or worse off in terms of disease progression than individuals 
with no or only a modest increase?  
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